GHK-Cu: A Copper Tripeptide With a Delivery Problem

The short version

GHK-Cu is a very small peptide — three amino acids (glycine, histidine, lysine) — bound to a single copper ion. You will also see it called copper tripeptide-1. The same GHK sequence occurs naturally inside type I collagen, the main structural protein of skin and tendon, which is the clue to what it does: at very low concentrations it signals skin cells to rebuild their scaffolding of collagen and elastin ^[4].

Of the two compounds on this desk, GHK-Cu has the strongest human evidence — but most of that evidence is topical (applied to the skin surface) and modest in scale. It comes with a built-in limitation: the peptide does not cross intact skin well on its own ^[8]. Topical copper-peptide cosmetics are legal and widely sold; injectable or systemic use is unapproved and research-only. The gene-expression data are striking on paper but rest on a methodology that needs careful reading ^[9]. A controlled hair-loss trial showed a real efficacy signal, but it used a combination product, not pure GHK-Cu ^[10]. This page summarizes the studies and lists no dose or regimen.

What it is

GHK-Cu is the linear tripeptide glycyl-L-histidyl-L-lysine, chelated one-to-one to a copper(II) ion. The copper is held by the histidine imidazole ring, the glycine alpha-amino nitrogen, and a backbone amide nitrogen, leaving the lysine side chain free. It carries a small positive charge. The bare GHK sequence appears endogenously within the alpha-2(I) chain of type I collagen and in a matrix protein called SPARC/osteonectin — so the body already uses this motif, and copper coordination is required for most of its reported activity ^[4].

In commerce it appears as topical cosmetic products (Copper Tripeptide-1, a legal ingredient in the US and EU) and as injectable research-grade material. The two forms have very different regulatory and evidentiary footings, and conflating them is a common source of overclaiming.

How it works

GHK-Cu plays two roles at once: it is a copper chaperone — a carrier that delivers copper where the body needs it — and a broad signaling molecule for repair. At picomolar-to-nanomolar concentrations it directly tells dermal fibroblasts, the skin's matrix-making cells, to synthesize collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing the enzymes that break matrix down (matrix metalloproteinases) against their natural inhibitors (TIMPs) ^[4]. The copper ion enables lysyl-oxidase-driven collagen and elastin cross-linking, plus a superoxide-dismutase-like antioxidant effect.

The gene-expression story is the most ambitious claim in the literature: a Connectivity Map analysis reported that GHK shifts expression of roughly 31.2% of human genes at a 50%-or-greater change threshold, about 59% upward and 41% downward, strongly stimulating ubiquitin-proteasome protein-quality-control pathways and DNA-repair and antioxidant gene sets ^[9]. Two corrections belong alongside that figure. The frequently quoted "approximately 4,000 genes" is an extrapolation; the verified 50%-threshold analysis reports on the order of 2,100 genes ^[9]. And gene-expression shifts in a database analysis need protein-level in vivo validation before they can be described as effects.

What the research shows

Skin regeneration. The canonical skin review documents GHK-Cu stimulating synthesis of collagen, dermatan sulfate, chondroitin sulfate and decorin; notes that plasma GHK falls from about 200 ng/mL at age 20 to about 80 ng/mL by age 60; and reports topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid ^[4]. A broader tissue-remodeling review from 2008 catalogues GHK's wound-healing effects across multiple models, including stimulation of VEGF, FGF-2 and nerve growth factor alongside the collagen signal ^[5].

Gene expression. The 2018 Connectivity Map analysis quantified the transcriptomic shift toward repair, protein-quality-control, DNA-fidelity and antioxidant programs, with the honest acknowledgment that an in-vitro gene-expression assay is not the same as a demonstrated clinical effect ^[9].

The delivery problem. A 2025 review confirms GHK's poor stratum-corneum permeability (clogP -2.24) as the central formulation challenge, reports procollagen synthesis up in 70% of GHK-Cu-treated subjects, and evaluates delivery strategies: palmitoylation raises lipophilicity (clogP to 1.14) and microneedle pretreatment allowed about 134 nanomoles of GHK to permeate versus none through intact skin ^[8]. The delivery problem is not solved, but it is being mapped.

Skin penetration quantified. A human skin penetration study measured copper delivery from GHK-Cu through dermatomed skin: about 136 micrograms per square centimeter permeated over 48 hours, with a measurable dermal depot of about 97 micrograms per square centimeter retained — quantifying both delivery and the copper depot that forms ^[11].

Hair — the strongest controlled signal. In a 6-month randomized trial of 45 men with androgenetic alopecia, a combination product of 5-aminolevulinic acid plus glycyl-histidyl-lysine peptide increased hair count by 52.6 (100 mg/mL) and 71.5 (50 mg/mL) versus only 9.6 for placebo, with no adverse events ^[10]. This is the most controlled human efficacy signal for a GHK-containing topical — but it is a combination formulation, not pure GHK-Cu.

Reported effects, cautions & safety

Topical copper-peptide products carry a long real-world safety record, but several cautions are well documented and belong in any honest account:

• No approved drug indication. There is no FDA- or EMA-approved therapeutic GHK-Cu product by any route. Topical copper tripeptide-1 is a legal cosmetic ingredient; injectable or systemic use is unapproved and research-only ^[8].
• Human evidence is topical and small-scale. Clinical data are limited to small topical dermatology trials and the single 45-patient combination hair-loss RCT; there is no validated human pharmacokinetic data for injectable or systemic GHK-Cu ^[10].
• Localized hyperpigmentation. Skin darkening has been reported with some topical copper-peptide applications, around 40% in one acne-scar microneedling study.
• Formulation incompatibility. Vitamin C / ascorbic acid and low-pH acids can destroy both actives through copper interactions — a real user-error risk in combination regimens.
• Theoretical copper accumulation. Prolonged systemic use raises a theoretical copper-balance concern, though no human copper-toxicity case attributed to GHK-Cu appears in the peer-reviewed record. The caveat applies most obviously to anyone with copper-overload conditions such as Wilson's disease ^[4].
• Single-investigator origin of foundational literature. A large share of mechanistic review work originates from one investigator and colleagues, which limits independent replication of the broader anti-aging and gene-expression claims ^[9].
• GHK versus GHK-Cu conflation. The free tripeptide and the copper chelate are frequently confused in secondary sources; copper coordination is required for most reported bioactivities, so the form used in a given study matters ^[4].

Where it fits in skin research

GHK-Cu is the matrix-and-skin specialist of this desk, and the compound with the strongest human footing — but that footing is mostly on the skin surface, where its own delivery limitation caps how far the evidence reaches ^[8]. Where GLOW combines GHK-Cu with two other peptides to extend coverage to angiogenesis and cell migration, the standalone GHK-Cu story is more focused and more tested, even if the evidence is still modest. Compare the two on the comparison page.